As health care professionals, we always have to strike a balance between risks and benefits.
Earlier, this lady said she had received cancer treatment. Usually, when a patient is suffering from a potentially deadly cancer, the health care professionals treating that patient will accept a higher level of adverse reactions and potential risks of mortality, because this is a somewhat desperate situation.
Let's take the example of a nonsteroidal antiinflammatory drug which relieves pain for certain people suffering from rheumatoid arthritis, a very debilitating form of arthritis. We accept somewhat higher levels of ADRs. However, if it is used to cure a tennis elbow, we do not want to have this lead to liver problems and liver transplants down the road. It is in that sense that we have to evaluate the data that is given to us. It is not because a drug has been withdrawn from the market in another country that we should absolutely have it withdrawn here, because the context for its use may not be the same.
As health care professionals, that is the kind of information we like to obtain in terms of feedback. In the final analysis, we are the ones who are faced with the patients, and we have to advise them and inform them of the risks and benefits involved in taking a given drug.